A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation

Premature Ejaculation Clinical Trial

Official title:
A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Study to Evaluate Systemic and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites, 2,6-Dimethylaniline (2,6-DMA) and O-Toluidine, in Female Healthy Volunteer Subjects Following Daily Application of 60 mg PSD502 or Placebo to the Vagina and Cervix for 7 Days

Status Completed

Clinical Trial Summary

A phase I, single-center, double-blind, randomized, placebo-controlled, safety and pharmacokinetic study to evaluate systemic and local vaginal exposure to lidocaine and prilocaine and the metabolites, 2,6-dimethylaniline (2,6-DMA) and o-toluidine, in female healthy volunteer subjects following daily application of 60 mg PSD502 or placebo to the vagina and cervix for seven days

Clinical Trial Description

The study drug is a metered-dose anesthetic spray, which is being developed for the treatment of premature ejaculation (PE). The use of anesthetic in topical creams has been well established. The use of a cream does not result in the concentrated drug being in direct contact with the cells, unlike the spray.

Seven clinical studies have already been carried out for the spray in the development of PE. These studies have demonstrated a prolongation of intravaginal ejaculatory latency time and no safety concerns for male patients or their female partners. The partners of clinical study participants have been asked to report health changes during the studies. Reports of vaginal numbness were uncommon; however, effects of the transfer to a partner cannot be excluded. This study is being conducted to investigate in detail the systemic exposure to PSD502 spray in order to assess safety in the female partner. The dose level has been chosen because the total dose applied to the male glans penis is 30 mg, and thus it is potentially possible that his partner could be exposed to this dose. Therefore, the 60 mg dose was chosen to provide safety information with a higher margin of exposure. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01184105
Study type	Interventional
Source	Plethora Solutions Ltd
Contact
Status	Completed
Phase	Phase 1
Start date	September 2010
Completion date	November 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02232425` - IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)	Phase 2
Completed	`NCT01439984` - Trial of PED-1 in Male Patients With Premature Ejaculation	Phase 3
Completed	`NCT01203202` - Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation	Phase 2
Completed	`NCT03942367` - Evaluation of the Safety and Effectiveness of the vPatch Device	N/A
Recruiting	`NCT06425211` - Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.	N/A
Completed	`NCT02939495` - The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy	Phase 4
Completed	`NCT02572037` - Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research
Recruiting	`NCT02581826` - Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation	Phase 2
Terminated	`NCT00983736` - Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation	Phase 3
Completed	`NCT00556478` - Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation	Phase 2/Phase 3
Completed	`NCT00549211` - A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.	Phase 1
Not yet recruiting	`NCT05556083` - Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)	Phase 2
Completed	`NCT03304808` - Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0	N/A
Completed	`NCT00861484` - Proof of Mechanism in ELT	Phase 1
Completed	`NCT02984592` - Effect of Exercise on Premature Ejaculation	N/A
Recruiting	`NCT02571101` - A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation	Phase 2
Completed	`NCT03174470` - Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle	N/A
Completed	`NCT02794454` - A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health	N/A
Completed	`NCT02297152` - A New Treatment for Premature Ejaculation?	N/A
Not yet recruiting	`NCT00656552` - Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation	Phase 0

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.